H
81.46
0.07 (0.09%)
| Previous Close | 81.39 |
| Open | 81.51 |
| Volume | 651,482 |
| Avg. Volume (3M) | 1,560,230 |
| Market Cap | 18,920,876,032 |
| Price / Earnings (TTM) | 27.80 |
| Price / Earnings (Forward) | 18.45 |
| Price / Sales | 4.63 |
| Price / Book | 3.56 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 - 11 Nov 2024 |
| Profit Margin | 17.59% |
| Operating Margin (TTM) | 24.36% |
| Diluted EPS (TTM) | 3.32 |
| Quarterly Revenue Growth (YOY) | 4.50% |
| Quarterly Earnings Growth (YOY) | 97.10% |
| Total Debt/Equity (MRQ) | 49.41% |
| Current Ratio (MRQ) | 3.99 |
| Operating Cash Flow (TTM) | 1.18 B |
| Levered Free Cash Flow (TTM) | 757.96 M |
| Return on Assets (TTM) | 6.45% |
| Return on Equity (TTM) | 13.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Hologic, Inc. | Mixed | Bullish |
Stockmoo Score
0.2
| Analyst Consensus | 2.0 |
| Insider Activity | 0.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.20 |
|
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.79% |
| % Held by Institutions | 103.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Raymond James, 16.62%) | Buy |
| Median | 90.00 (10.48%) | |
| Low | 82.00 (Evercore ISI Group, 0.66%) | Hold |
| Average | 89.11 (9.39%) | |
| Total | 5 Buy, 4 Hold | |
| Avg. Price @ Call | 79.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2024 | 94.00 (15.39%) | Buy | 78.80 |
| Mizuho | 05 Nov 2024 | 87.00 (6.80%) | Buy | 78.80 |
| 04 Oct 2024 | 90.00 (10.48%) | Buy | 80.24 | |
| RBC Capital | 05 Nov 2024 | 89.00 (9.26%) | Hold | 78.80 |
| Raymond James | 05 Nov 2024 | 95.00 (16.62%) | Buy | 78.80 |
| UBS | 05 Nov 2024 | 90.00 (10.48%) | Hold | 78.80 |
| Needham | 15 Oct 2024 | 90.00 (10.48%) | Buy | 81.66 |
| 17 Sep 2024 | 90.00 (10.48%) | Buy | 82.00 | |
| Leerink Partners | 08 Oct 2024 | 90.00 (10.48%) | Buy | 80.26 |
| Citigroup | 01 Oct 2024 | 85.00 (4.35%) | Hold | 80.56 |
| Evercore ISI Group | 01 Oct 2024 | 82.00 (0.66%) | Hold | 80.56 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANDERSON ERIK S | 79.39 | 79.03 | 2,982 | 237,655 |
| COHN BENJAMIN JORDAN | 79.39 | 79.03 | 884 | 70,311 |
| GRIFFIN JOHN M. | 79.39 | 79.03 | -3,593 | -279,331 |
| MACMILLAN STEPHEN P | 79.39 | 79.03 | -34,984 | -2,733,637 |
| MITCHELL ESSEX D | 79.39 | 79.03 | 6,216 | 496,292 |
| OBERTON KARLEEN MARIE | 79.39 | 79.03 | -4,312 | -334,277 |
| SCHNEIDERS JENNIFER M | 79.39 | 79.03 | 6,016 | 477,705 |
| SCHNITTKER BRANDON | 79.39 | 79.29 | 2,696 | 214,049 |
| VERSTREKEN JAN | 79.39 | 79.03 | 769 | 64,216 |
| Aggregate Net Quantity | -23,326 | |||
| Aggregate Net Value ($) | -1,787,016 | |||
| Aggregate Avg. Buy ($) | 79.39 | |||
| Aggregate Avg. Sell ($) | 79.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ANDERSON ERIK S | Officer | 11 Nov 2024 | Acquired (+) | 4,723 | 79.39 | 374,959 |
| COHN BENJAMIN JORDAN | Officer | 11 Nov 2024 | Acquired (+) | 1,180 | 79.39 | 93,680 |
| GRIFFIN JOHN M. | Officer | 11 Nov 2024 | Acquired (+) | 6,298 | 79.39 | 499,998 |
| MITCHELL ESSEX D | Officer | 11 Nov 2024 | Acquired (+) | 11,021 | 79.39 | 874,957 |
| OBERTON KARLEEN MARIE | Officer | 11 Nov 2024 | Acquired (+) | 9,447 | 79.39 | 749,997 |
| SCHNEIDERS JENNIFER M | Officer | 11 Nov 2024 | Acquired (+) | 6,298 | 79.39 | 499,998 |
| SCHNITTKER BRANDON | Officer | 11 Nov 2024 | Acquired (+) | 2,834 | 79.39 | 224,991 |
| VERSTREKEN JAN | Officer | 11 Nov 2024 | Acquired (+) | 6,298 | 79.39 | 499,998 |
| MACMILLAN STEPHEN P | Officer | 11 Nov 2024 | Acquired (+) | 39,677 | 79.39 | 3,149,957 |
| ANDERSON ERIK S | Officer | 08 Nov 2024 | Disposed (-) | 1,397 | 78.76 | 110,028 |
| COHN BENJAMIN JORDAN | Officer | 08 Nov 2024 | Disposed (-) | 190 | 78.76 | 14,964 |
| GRIFFIN JOHN M. | Officer | 08 Nov 2024 | Disposed (-) | 9,299 | 78.76 | 732,389 |
| MITCHELL ESSEX D | Officer | 08 Nov 2024 | Disposed (-) | 4,383 | 78.76 | 345,205 |
| OBERTON KARLEEN MARIE | Officer | 08 Nov 2024 | Disposed (-) | 12,598 | 78.76 | 992,218 |
| SCHNEIDERS JENNIFER M | Officer | 08 Nov 2024 | Disposed (-) | 125 | 78.76 | 9,845 |
| VERSTREKEN JAN | Officer | 08 Nov 2024 | Disposed (-) | 4,928 | 78.76 | 388,129 |
| MACMILLAN STEPHEN P | Officer | 08 Nov 2024 | Disposed (-) | 68,447 | 78.76 | 5,390,886 |
| ANDERSON ERIK S | Officer | 07 Nov 2024 | Disposed (-) | 344 | 79.29 | 27,276 |
| COHN BENJAMIN JORDAN | Officer | 07 Nov 2024 | Disposed (-) | 106 | 79.29 | 8,405 |
| GRIFFIN JOHN M. | Officer | 07 Nov 2024 | Disposed (-) | 592 | 79.29 | 46,940 |
| MITCHELL ESSEX D | Officer | 07 Nov 2024 | Disposed (-) | 422 | 79.29 | 33,460 |
| OBERTON KARLEEN MARIE | Officer | 07 Nov 2024 | Disposed (-) | 1,161 | 79.29 | 92,056 |
| SCHNEIDERS JENNIFER M | Officer | 07 Nov 2024 | Disposed (-) | 157 | 79.29 | 12,449 |
| SCHNITTKER BRANDON | Officer | 07 Nov 2024 | Disposed (-) | 138 | 79.29 | 10,942 |
| VERSTREKEN JAN | Officer | 07 Nov 2024 | Disposed (-) | 601 | 79.29 | 47,653 |
| MACMILLAN STEPHEN P | Officer | 07 Nov 2024 | Disposed (-) | 6,214 | 79.29 | 492,708 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 14 Nov 2024 | Announcement | Hologic to Webcast Presentations at Upcoming Investor Conferences |
| 04 Nov 2024 | Announcement | Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024 |
| 14 Oct 2024 | Announcement | Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women’s Health |
| 04 Oct 2024 | Announcement | Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024 |
| 30 Sep 2024 | Announcement | Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month |
| 29 Aug 2024 | Announcement | Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |